CN104740138A - Composition containing aloe, probiotics and prebiotics and application of composition - Google Patents
Composition containing aloe, probiotics and prebiotics and application of composition Download PDFInfo
- Publication number
- CN104740138A CN104740138A CN201310754269.4A CN201310754269A CN104740138A CN 104740138 A CN104740138 A CN 104740138A CN 201310754269 A CN201310754269 A CN 201310754269A CN 104740138 A CN104740138 A CN 104740138A
- Authority
- CN
- China
- Prior art keywords
- aloe
- lactobacillus
- medicine
- compositions
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a composition and an application thereof in regulating intestinal flora of animals. The composition contains aloe, probiotics and prebiotics, wherein the mass ratio of the aloe to the probiotics to the prebiotics is (6 to 3 to 1)-(6 to 1 to 3). The inventor discovers that the composition disclosed by the invention can effectively promote the proliferation of useful bacteria such as bifidobacterium and lactobacilli in animal intestines, so as to effectively regulate the intestinal flora of animals; therefore, the composition can be used for preventing or treating diabetes on the basis of the effect of the intestinal flora.
Description
Technical field
The present invention relates to composition and use thereof, particularly, relate to aloe composition and preparing the purposes in medicine and food, medicine and food.
Background technology
According to research reports, human body cell 90% is not the cell of people oneself, but microorganism, the microorganism of the mankind and its parachorium forms one " superior biological body " jointly.Therefore can say that human body has two cover genomes, a set of is oneself, and a set of is microorganism.Intestinal microbial population composition, structure and ratio and health and disease generation close relation.Different intestinal microbial population spectrum can be caused a disease, can also diseases prevention; Can cause fat fat, also can cause and become thin; Can induced Diabetic, also can prevent diabetes.Different flora spectrums, produces different physiology and pathologic effect.They are healthy and the bringing out or the factor that starts of disease; Also be healthy and disease " weatherglass ".At present, research confirms that the various diseases of human body is as all closely related with intestinal microbial population in diabetes, hypertension, hyperlipidemia, cancer etc.
But, regulate the research of microbial population of animal intestinal tract aspect still to need deeply at present.
Summary of the invention
The present invention is intended at least to solve one of technical problem existed in prior art.For this reason, one object of the present invention is the means proposing a kind of effective adjustment microbial population of animal intestinal tract.
Thus, in one aspect of the invention, the invention provides a kind of compositions.According to embodiments of the invention, said composition comprises Aloe, probiotic bacteria and prebiotics, and wherein, the mass ratio of described Aloe, probiotic bacteria and prebiotics is 6:3:1 ~ 6:1:3.According to some embodiments of the present invention, compositions of the present invention effectively can promote the propagation of the profitable strains such as Bifidobacterium in animal intestinal, Lactobacillus, Lactococcus, namely effectively microbial population of animal intestinal tract can be regulated, and then based on the effect of intestinal microbial population, play effect of prevention or treatment diabetes.
It should be noted that, the animal species of term " animal " indication in expression way " adjustment microbial population of animal intestinal tract " used in this article is not particularly limited.According to embodiments of the invention, this animal can be any animal with intestinal organ, and preferred mammal, more preferably rat, mice, people, optimum is chosen.In addition, used in this article expression way " prevention or treatment " mainly refers to prevention or adjuvant therapy of diabetes.
According to embodiments of the invention, namely the source of Aloe provides form to be not particularly limited, such as, directly by commercial acquisition, also can provide with various aloe products.According to some embodiments of the present invention, described Aloe be selected from Aloe powder, Aloe juice, Aloe gel, Aloe extract at least one form provide.
According to embodiments of the invention, the kind of probiotic bacteria is not particularly limited, as long as effectively can regulate microbial population of animal intestinal tract, those skilled in the art can select flexibly according to practical situation.According to some embodiments of the present invention, described probiotic bacteria is prebiotic Pseudomonas common in human body, such as but not limited to bacillus faecalis genus, Eubacterium, fusobacterium, Fusobacterium, Luo Sibairui Bordetella, Coprecoccus, Bifidobacterium, Butyrivibrio, Lactobacillus or the Lactococcus of dwelling.According to concrete examples more of the present invention, described probiotic bacteria is for being selected from Eubacterium rectale, food glucose Luo Sibairui Salmonella, intestinal Luo Sibairui Salmonella, Pu Shi is dwelt bacillus faecalis, clostridium butyricum, Bacillus coagulans, bifidobacterium bifidum, bifidobacterium infantis, long bifidus bacillus, short bifidus bacillus, bifidobacterium adolescentis, Lactobacillus delbrueckii subsp.bulgaricus, bacillus acidophilus, streptococcus thermophilus, L. casei casei, Lactobacillus reuteri, Bifidobacterium lactis, lactobacillus casei, Lactobacillus crispatus, lactobacillus delbruockii subspecies bulgaricus, Lactobacillus fermenti, Lactobacillus gasseri, lactobacillus helveticus, Lactobacillus johnsonii, Lactobacillus plantarum, lactobacillus rhamnosus, Lactobacillus salivarius, P. freudenreichii ssp subspecies, Lactococcus lactis subsp.lactis, lactococcus lactis subsp.cremoris, lactococcus lactis biacetyl subspecies, the at least one of leuconostoc mesenteroides subsp mesenteroides.
According to embodiments of the invention, the kind of described prebiotics is not particularly limited, as long as effectively can promote the growth of profitable strain.According to some embodiments of the present invention, described prebiotics is at least one being selected from inulin, propolis, oligochitosan, oligofructose, oligomeric galactose, oligomeric xylose.Thus, can the growth of effective stimulus profitable strain.
In a second aspect of the present invention, the invention provides foregoing compositions and regulating the purposes in microbial population of animal intestinal tract.Inventor is surprised to find, compositions of the present invention can significantly improve the profitable strain quantity in described animal intestinal, regulates microbial population of animal intestinal tract, and then based on the effect of intestinal microbial population, the blood sugar concentration of the described animal of effective reduction, thus effectively prevent or treatment diabetes.
According to embodiments of the invention, take compositions of the present invention without any toxic and side effects, thus the dosage of described compositions is not particularly limited, and those skilled in the art can select flexibly according to the health status of administration object.According to some embodiments of the invention, described compositions is carried out administration with the dosage of 0.5g Aloe/kg/d to described animal.Thus, obviously increased by the quantity of profitable strain in administration animal intestinal, namely compositions of the present invention regulates the Be very effective of microbial population of animal intestinal tract.
It should be noted that, term " administration " used in this article should make broad understanding, except the drug administration of routine, to feed for can be understood as when compositions or food or to provide this food animal.
In a third aspect of the present invention, the invention provides foregoing compositions and preparing the purposes in medicine.According to embodiments of the invention, described medicine is for regulating microbial population of animal intestinal tract.
Said medicine can be used in regulating microbial population of animal intestinal tract, and then can play hypoglycemic effect by the effect of intestinal microbial population.Thus, according to some embodiments of the present invention, described medicine is used for prevention or treatment diabetes.
According to embodiments of the invention, the dosage of described medicine is not particularly limited, as long as effectively can regulate microbial population of animal intestinal tract.According to concrete examples more of the present invention, described medicine is carried out administration with the dosage of 0.5g Aloe/kg/d to described animal.Thus, significantly increased by the profitable strain quantity in administration animal intestinal, blood sugar concentration obviously reduces.
In a fourth aspect of the present invention, present invention also offers a kind of medicine.According to embodiments of the invention, described pharmaceutical pack contains: foregoing compositions; And pharmaceutically acceptable excipient.Inventor is surprised to find, and medicine of the present invention can significantly improve by the quantity of the probiotic bacterias such as bacillus bifidus, Lactococcus, lactobacillus in administration animal intestinal, regulates the intestinal microbial population of animal, and then is effectively prevented by the effect of intestinal microbial population or treated diabetes.
According to embodiments of the invention, the kind of excipient is not particularly limited, as long as medicine can be made to form the dosage form of easily carrying out administration.According to concrete examples more of the present invention, described excipient is at least one being selected from binding agent, filler, film-coating polymer, plasticizer, fluidizer, disintegrating agent and lubricant.
According to embodiments of the invention, the dosage form of medicine of the present invention is not particularly limited, as long as can be convenient to carry out administration.According to concrete examples more of the present invention, described medicine is in the form of at least one being selected from capsule, pill, tablet, granule, liquid oral, oral pastes, aerosol and spray.According to preferred embodiments more of the present invention, described medicine is the form of capsule.Thus, be easy to carry out administration.
According to embodiments of the invention, described medicine is for regulating microbial population of animal intestinal tract.And then, hypoglycemic effect can be played by the effect of intestinal microbial population.Thus, according to other embodiments of the present invention, described medicine is used for prevention or treatment diabetes.
According to embodiments of the invention, the dosage of medicine of the present invention is not particularly limited, and in practical application, can select flexibly according to the health status of administration object.According to some embodiments of the present invention, the dosage of described medicine is 0.5g Aloe/kg/d.Thus, significantly increased by the quantity of the probiotic bacterias such as bacillus bifidus, lactobacillus, Lactococcus in administration animal intestinal, regulate the Be very effective of microbial population of animal intestinal tract, and then based on the effect of intestinal microbial population, can effectively reduce by the blood sugar concentration of administration animal, thus prevention or treatment diabetes.
In a fifth aspect of the present invention, present invention also offers a kind of food.According to embodiments of the invention, described food product packets is containing foregoing compositions; And acceptable additive in bromatology.Inventor finds, food of the present invention can significantly improve by the quantity of the probiotic bacteria such as bacillus bifidus, Ruminococcus in administration animal intestinal, effectively regulates the intestinal microbial population of animal, and then is effectively prevented by the effect of intestinal microbial population or treated diabetes.
It should be noted that, term " food " used in this article should make broad understanding, its can be any can by the form eaten, namely except the food form of routine, food of the present invention can also be health product, beverage etc.
In a sixth aspect of the present invention, present invention also offers foregoing medicine or the purposes of food in adjustment microbial population of animal intestinal tract.According to embodiments of the invention, to the foregoing medicine of the present invention of animals administer or food, can significantly improve by the quantity of the probiotic bacterias such as bacillus bifidus, Lactococcus, lactobacillus in administration animal intestinal, the intestinal microbial population of effective adjustment animal, and then effectively prevent by the effect of intestinal microbial population or treat diabetes.
According to a seventh aspect of the invention, present invention also offers a kind of method regulating microbial population of animal intestinal tract.According to embodiments of the invention, the method is to described animals administer compositions of the present invention noted earlier, medicine or food.According to embodiments of the invention, utilize method of the present invention can significantly improve by the quantity of the probiotic bacterias such as bacillus bifidus, Lactococcus, lactobacillus in administration animal intestinal, the intestinal microbial population of effective adjustment animal, and then effectively prevent by the effect of intestinal microbial population or treat diabetes.
In addition, according to embodiments of the invention, described compositions and comprise food of the present invention or the medicine of said composition, regulates the effect of microbial population of animal intestinal tract to be better than the action effect of the Aloe of single component, probiotic bacteria or prebiotics.
Also it should be noted that, compositions of the present invention, medicine, food and the purposes in adjustment microbial population of animal intestinal tract thereof, the present inventor just surprisingly finds through arduous creative work and a large amount of experimental works just.
The present invention at least one of has the following advantages:
1, compositions of the present invention, all raw materials are taken at nature, it is natural to come from, and not containing any chemicals, have no side effect, safe and reliable; Raw material sources are extensively easy to get, and prescription compatibility is scientific and reasonable, and determined curative effect has synergistic function; And preparation technology is simple, storing and application safety, low production cost, is easily esthetically acceptable to the consumers;
2, compositions of the present invention, medicine and food; eating test through animal function test and crowd all proves without any side effects; Fasting Glucose can be made significantly to decline; there is significant hypoglycemic activity, meet requirement and the development trend of health product, be suitable for hyperglycemia, obese people and elderly population etc.; taken by daily; from the angle of effecting a permanent cure, by regulating intestinal canal flora, play hypoglycemic effect, finally reach the object protected the health.
3, the present invention is by reasonable assembly to pure natural raw material, achieves easily, the health-care effect such as significant blood sugar lowering, and drug effect is obvious, safety good, steady quality, and product can be preserved for a long time, for people's daily health caring provides new selection.
Additional aspect of the present invention and advantage will part provide in the following description, and part will become obvious from the following description, or be recognized by practice of the present invention.
Detailed description of the invention
Embodiments of the invention are described below in detail.Embodiment described below is exemplary, only for explaining the present invention, and can not be interpreted as limitation of the present invention.Unreceipted concrete technology or condition in embodiment, according to the technology described by the document in this area or condition or carry out according to product description.Agents useful for same or the unreceipted production firm person of instrument, being can by the conventional products of commercial acquisition.
Embodiment 1
According to the formula shown in table 1, prepare compositions according to following technique.
Table 1 composite formula of the present invention (unit of weight of raw material: part)
Concrete operation step is as follows:
1, Aloe powder
The Aloe powder that the present invention adopts, can derive from market, also can prepare voluntarily, preparation method is common method.
2, Aloe clostridium butyricum bee glue capsule
Clostridium butyricum strain is through liquid culture, collect and washing thalline, drying is prepared into active microbe powder, ratio according to 6/3/1 stirs Aloe powder, clostridium butyricum mycopowder and propolis, then No. 0 capsulation is used, obtain Aloe clostridium butyricum bee glue capsule, wherein, clostridium butyricum viable count is not less than 1.0 × 10
8cFU/g.
3, Aloe bacillus bifidus inulin capsule
Bifidobacterium species is through liquid culture, collect and washing thalline, drying is prepared into active microbe powder, ratio according to 3/1/1 stirs Aloe powder, Bifidobacteria powder and inulin, then No. 0 capsulation is used, obtain Aloe bacillus bifidus inulin capsule, wherein, the number of active bifid bacteria is not less than 1.0 × 10
8cFU/g.
4, aloe plant lactobacillus chitosan oligosaccharide capsule
Lactobacillus plantarum strain is through liquid culture, collect and washing thalline, drying is prepared into active microbe powder, ratio according to 6/3/1 stirs Aloe powder, Lactobacillus plantarum mycopowder and oligochitosan, then No. 0 capsulation is used, obtain aloe plant lactobacillus chitosan oligosaccharide capsule, wherein, Lactobacillus plantarum viable count is not less than 1.0 × 10
8cFU/g.
5, Aloe intestinal Luo Sibairui Salmonella oligofructose capsule
Intestinal Luo Sibairui Salmonella strain is through liquid culture, collect and washing thalline, drying is prepared into active microbe powder, ratio according to 6/3/1 stirs Aloe powder, intestinal Luo Sibairui Salmonella mycopowder and oligofructose, then No. 0 capsulation is used, obtain Aloe intestinal Luo Sibairui Salmonella oligofructose capsule, wherein, intestinal Luo Sibairui Salmonella viable count is not less than 1.0 × 10
8cFU/g.
6, Aloe bacillus acidophilus oligomeric galactose capsule
Lactobacillus acidophilus species is through liquid culture, collect and washing thalline, drying is prepared into active microbe powder, ratio according to 12/5/3 stirs Aloe powder, bacillus acidophilus's mycopowder and oligomeric galactose, then No. 0 capsulation is used, obtain Aloe bacillus acidophilus oligomeric galactose capsule, wherein, live lactobacillus acidophilus number is not less than 1.0 × 10
8cFU/g.
7, Aloe Lactobacillus fermenti oligomeric xylose capsule
Lactobacillus fermenti strain is through liquid culture, collect and washing thalline, drying is prepared into active microbe powder, ratio according to 12/3/5 stirs Aloe powder, Lactobacillus fermenti mycopowder and oligomeric xylose, then No. 0 capsulation is used, obtain Aloe Lactobacillus fermenti oligomeric xylose capsule, wherein, Lactobacillus fermenti viable count is not less than 1.0 × 10
8cFU/g.
8, Aloe Bacillus coagulans oligofructose capsule
Bacillus coagulans strain is through liquid culture, collect and washing thalline, drying is prepared into active microbe powder, ratio according to 6/3/1 stirs Aloe powder, Bacillus coagulans mycopowder and oligofructose, then No. 0 capsulation is used, obtain Aloe Bacillus coagulans oligofructose capsule, wherein, coagulated bacillus living number is not less than 1.0 × 10
8cFU/g.
9, Aloe streptococcus thermophilus inulin capsule
Streptococcus thermophilus strain is through liquid culture, collect and washing thalline, drying is prepared into active microbe powder, ratio according to 6/3/1 stirs Aloe powder, streptococcus thermophilus mycopowder and inulin, then No. 0 capsulation is used, obtain Aloe streptococcus thermophilus inulin capsule, wherein, streptococcus thermophilus viable count is not less than 1.0 × 10
8cFU/g.
10, Aloe Lactobacillus reuteri chitosan oligosaccharide capsule
Lactobacillus reuteri strain is through liquid culture, collect and washing thalline, drying is prepared into active microbe powder, ratio according to 6/3/1 stirs Aloe powder, Lactobacillus reuteri mycopowder and oligochitosan, then No. 0 capsulation is used, obtain Aloe Lactobacillus reuteri chitosan oligosaccharide capsule, wherein, Lactobacillus reuteri viable count is not less than 1.0 × 10
8cFU/g.
11, aloe plant lactobacillus inulin pressed candy
Aloe powder, Lactobacillus plantarum powder, inulin are filtered through 80 mesh sieves, proportion scale 6:3:1, mixed mixing time 15 minutes.Time dry, temperature is 60 DEG C, and pellet moisture is 0.5%, and control ambient humidity during compression molding, relative humidity is 60%.
Embodiment 2: determination of acute toxicity
Utilize 6 week age specific-pathogen free (SPF) SD rat to carry out acute toxicity test, concrete operations are as follows:
Each composition suspendedly float in the methocel solution of 0.5% by what prepare in embodiment 1, respectively with the dosage of 1g/kg, 5g/kg and 10g/kg once by oral administration to 5 the SD rats often organized, observe the death of rat, clinical symptoms and body weight change, and carry out blood test and hematochemical test, when postmortem, any abnormal phenomena of macroscopy thorax abdomen gastrointestinal tissue.
Experimental result: each compositions of the present invention does not cause any specific clinical symptoms, body weight change or death, and blood test, hematochemical test and postmortem also do not change.Therefore, due to until the dosage of 10g/kg can not cause any poisoning change of rat, can judge that its median lethal dose(LD 50) (LD50) is far longer than 10g/kg, each compositions that the present invention relates to is rated as safety non-toxic material.
Embodiment 3: mediator's intestinal microbial population functional experiment
According to the regulating intestinal canal flora function human experiment experimental evaluation way of Ministry of Public Health " health food inspection and assessment technical specification (2003) ", evaluate each compositions prepared in embodiment 1, concrete operations are as follows:
1. test-meal experiment grouping
Test-meal experiment grouping situation is as shown in table 2:
Table 2 test-meal experiment grouped table
2. human experiment experimental technique
Experimenter is divided at random 12 groups, often organizes 20 people, before experimenter's test-meal, all asepticly take experimenter's feces, through 16SrDNA order-checking inspection intestinal microbial population, as the reference of background level.
By the grouping situation of table 2, group 1 takes matched group, group 2 takes combination 1, and group 3 takes combination 2, group 4 takes combination 3, and group 5 takes combination 4, and group 6 takes combination 5, group 7 takes combination 6, and group 8 takes combination 7, and group 9 takes combination 8, group 10 takes combination 9, and group 11 takes combination 10, and group 12 takes combination 11, after 4 weeks, take experimenter's feces, through 16SrDNA order-checking inspection intestinal microbial population, contrast with background level, contrast the multiple that its relative abundance increases.
3. intestinal microbial population detection method
First fecal sample carries out DNA extraction, V3 ~ V5 region of pcr amplification 16SrDNA, then with 454 platform order-checkings, and order-checking direction V5->V3.Average 7795 tag of each sample initial data, read long about 400bp.The final tag number average out to 3235 for analyzing, reads long about 265bp.
16S analyzes main mothur software (http://www.mothur.org/wiki/Mothur_manual) that adopts and comprises Quality Control, OTU cluster, the analyses such as annotation, and on the basis completing data species taxonomy, analyzes the relative abundance of each species.
4. experimental result
Experimental result is as shown in table 3 below:
The sequencing data abundance contrast (improving multiple compared with background level) of each Pseudomonas of table 3 people intestinal microbial population
From the data of table 3, taken the experimental group of each compositions relative to matched group, the probiotic bacteria numbers such as Eubacterium, bacillus faecalis of dwelling genus, Luo Sibairui Bordetella, Luo Si Bordetella, genus lactubacillus all have obvious increase.Show thus, compositions of the present invention can regulate the Be very effective of microbial population of animal intestinal tract.
Embodiment 4: blood sugar lowering zoopery
According to the auxiliary hyperglycemic function zoopery evaluation method of Ministry of Public Health " health food inspection and assessment technical specification (2003) ", evaluate each compositions prepared in embodiment 1, concrete operations are as follows:
1, test method
Get male SD rat 80, prepare low dose of streptozotocin according to standard method and cause diabetes rat model, after three days, be divided into 8 groups at random according to rat blood sugar value, often organize 10.Each group of continuous gastric infusion 8 days, every day 1 time, blank group gives equivalent distilled water, and last two hours after administration gets blood, measures blood glucose value.
2, subjects
Blank group: give distilled water;
Contrast 1 group: give metformin, dosage is 300mg/kg;
Contrast 2 groups: give Aloe powder, dosage is 300mg/kg;
Contrast 3 groups: give clostridium butyricum, dosage is 300mg/kg
Contrast 4 groups: give propolis, dosage is 300mg/kg
Contrast 5 groups: give Aloe powder 0.5g Aloe/kg/d, clostridium butyricum 150mg/kg, wherein, clostridium butyricum viable count is not less than 1.0 × 10
8cFU/g;
Experimental group 1: give combination 1(0.5g Aloe/kg/d of the present invention, propolis 80mg/kg, clostridium butyricum 150mg/kg, wherein, clostridium butyricum viable count is not less than 1.0 × 10
8cFU/g).
Experimental group 2: give combination 2(Lactobacillus plantarum 150mg/kg of the present invention, wherein Lactobacillus plantarum viable count is not less than 1.0 × 10
8cFU/ days, inulin: 1.2g/ days, 0.5g Aloe/kg/d)
3, experimental result
Each group of hypoglycemic result is as shown in table 4.
Table 4 respectively group blood sugar decreasing effect compares
Note: (1) compares * P<0.01 with blank group; (2) compare with blank group
Δp<0.05
The result of table 4 shows, contrast 1 group, contrast 2 groups, contrast 3 groups, contrast 4 groups, contrast 5 groups and experimental group 1, the hyperglycemia of experimental group 2 pairs of Experimental Diabetes of Mices all has decline effect, compositions of the present invention, and the hyperglycemia of metformin to Experimental Diabetes of Mice has extremely significant decline effect, the experimental result of associative list 2, illustrate that compositions of the present invention significantly increases probiotic bacteria flora number, and the increase of probiotic bacteria flora result in the reduction of blood glucose, show compositions of the present invention and there is hypoglycemic function, relative to single Aloe powder, probiotic bacteria or its combination, the action effect of compositions of the present invention in reduction experiment mice blood glucose is better, Aloe in the present composition is described, probiotic bacteria, prebiotics has synergistic function, the present invention has obvious technical advantage, there is significant auxiliary therapeutic action.
Embodiment 5: blood sugar lowering human experiment is tested
According to Ministry of Public Health " health food inspection and assessment technical specification (2003) ", carry out the experiment of blood sugar lowering human experiment, concrete operations are as follows:
1, sample:
The sample of this test is provided by Shenzhen Huada Genetic Technology Co., Ltd, prepares soft capsule by embodiments of the invention 1.
2, human experiment and test method:
Select 120 routine type Ⅱdiabetes mellitus people, wherein male 80 people by the principle of voluntariness, women 40 people, the range of age 43-75 year, without complication such as severe cardiac Liver and kidney, contrast design after taking in before test-meal.Experimenter's former medicine kind, diet control and activity are constant, by the grouping situation of table 2, often organize 10 people, group 1 takes matched group, group 2 takes combination 1, and group 3 takes combination 2, and group 4 takes combination 3, group 5 takes combination 4, and group 6 takes combination 5, and group 7 takes combination 6, group 8 takes combination 7, and group 9 takes combination 8, and group 10 takes combination 9, group 11 takes combination 10, and group 12 takes combination 11, every day 2 times, each 3, Yu Zao, evening bfore meals, take 30 days continuously.The change of monitoring patient blood pressure, defecation, body weight, and the blood glucose (with glucose oxidase method) measuring empty stomach and 2 hours after the meal.
3, judgment criteria:
Effective: fundamental symptoms disappears, on an empty stomach or the blood glucose of 2 hours after the meal comparatively treat before decline and be no more than 30.0%.
Effective: fundamental symptoms obviously improves, on an empty stomach and the blood glucose of 2 hours after the meal comparatively treat before decline and be no more than 10.0%.
Invalid: fundamental symptoms is not improved, on an empty stomach and the blood glucose of 2 hours after the meal comparatively treat before decline and be less than 10.0%.
4, human experiment result
Experimental result is as shown in table 5:
Table 5 foretastes crowd's blood glucose test results
As shown in Table 5, compared with before test-meal, after test-meal 30 days compositionss of the present invention, Fasting Glucose and 2h-plasma glucose have obvious reduction, comparatively have pole significant difference (P<0.01) before test-meal.Show thus, compositions of the present invention by improving intestinal microflora thus effectively reducing blood glucose, can have obvious Hyperglycemic health care function, and to the harmless effect of tested population health.
In the description of this description, specific features, structure, material or feature that the description of reference term " embodiment ", " some embodiments ", " example ", " concrete example " or " some examples " etc. means to describe in conjunction with this embodiment or example are contained at least one embodiment of the present invention or example.In this manual, identical embodiment or example are not necessarily referred to the schematic representation of above-mentioned term.And the specific features of description, structure, material or feature can combine in an appropriate manner in any one or more embodiment or example.
Although illustrate and describe embodiments of the invention, those having ordinary skill in the art will appreciate that: can carry out multiple change, amendment, replacement and modification to these embodiments when not departing from principle of the present invention and aim, scope of the present invention is by claim and equivalents thereof.
Claims (10)
1. a compositions, is characterized in that, comprises Aloe, probiotic bacteria and prebiotics, and wherein, the mass ratio of described Aloe, probiotic bacteria and prebiotics is 6:3:1 ~ 6:1:3.
2. compositions according to claim 1, is characterized in that, described Aloe be selected from Aloe powder, Aloe juice, Aloe gel, Aloe extract at least one form provide,
Optionally, described probiotic bacteria is at least one being selected from dwell bacillus faecalis genus, Eubacterium, fusobacterium, Fusobacterium, Luo Sibairui Bordetella, Coprecoccus, Bifidobacterium, Butyrivibrio, Lactobacillus, Lactococcus,
Optionally, described probiotic bacteria is for being selected from Eubacterium rectale, food glucose Luo Sibairui Salmonella, intestinal Luo Sibairui Salmonella, Pu Shi is dwelt bacillus faecalis, clostridium butyricum, Bacillus coagulans, bifidobacterium bifidum, bifidobacterium infantis, long bifidus bacillus, short bifidus bacillus, bifidobacterium adolescentis, Lactobacillus delbrueckii subsp.bulgaricus, bacillus acidophilus, streptococcus thermophilus, L. casei casei, Lactobacillus reuteri, Bifidobacterium lactis, lactobacillus casei, Lactobacillus crispatus, lactobacillus delbruockii subspecies bulgaricus, Lactobacillus fermenti, Lactobacillus gasseri, lactobacillus helveticus, Lactobacillus johnsonii, Lactobacillus plantarum, lactobacillus rhamnosus, Lactobacillus salivarius, P. freudenreichii ssp subspecies, Lactococcus lactis subsp.lactis, lactococcus lactis subsp.cremoris, lactococcus lactis biacetyl subspecies, the at least one of leuconostoc mesenteroides subsp mesenteroides,
Optionally, described prebiotics is at least one being selected from inulin, propolis, oligochitosan, oligofructose, oligomeric galactose, oligomeric xylose.
3. the compositions described in claim 1 or 2 is regulating the purposes in microbial population of animal intestinal tract.
4. purposes according to claim 3, is characterized in that, described compositions is carried out administration with the dosage of 0.5g Aloe/kg/d to described animal.
5. the compositions described in claim 1 or 2 is preparing the purposes in medicine, described medicine for regulating microbial population of animal intestinal tract,
Optionally, described medicine is used for prevention or treatment diabetes,
Optionally, described compositions is carried out administration with the dosage of 0.5g Aloe/kg/d to described animal.
6. a medicine, is characterized in that, comprises:
Compositions described in claim 1 or 2; And
Pharmaceutically acceptable excipient.
7. medicine according to claim 6, is characterized in that, described excipient is at least one being selected from binding agent, filler, film-coating polymer, plasticizer, fluidizer, disintegrating agent and lubricant,
Optionally, described medicine in the form of at least one being selected from capsule, pill, tablet, granule, liquid oral, oral pastes, aerosol and spray,
Optionally, described medicine for regulating microbial population of animal intestinal tract,
Optionally, described medicine is used for prevention or treatment diabetes,
Optionally, described medicine is carried out administration with the dosage of 0.5g Aloe/kg/d to described animal.
8. a food, is characterized in that, comprises:
Compositions described in claim 1 or 2; And
Acceptable additive in bromatology.
9. the medicine described in claim 6 or 7 or food according to claim 8, regulating the purposes in microbial population of animal intestinal tract.
10. regulate a method for microbial population of animal intestinal tract, it is characterized in that, to the compositions described in described animals administer claim 1 or 2, medicine described in claim 6 or 7 or food according to claim 8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310754269.4A CN104740138A (en) | 2013-12-31 | 2013-12-31 | Composition containing aloe, probiotics and prebiotics and application of composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310754269.4A CN104740138A (en) | 2013-12-31 | 2013-12-31 | Composition containing aloe, probiotics and prebiotics and application of composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104740138A true CN104740138A (en) | 2015-07-01 |
Family
ID=53580760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310754269.4A Pending CN104740138A (en) | 2013-12-31 | 2013-12-31 | Composition containing aloe, probiotics and prebiotics and application of composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104740138A (en) |
Cited By (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104970317A (en) * | 2015-07-08 | 2015-10-14 | 蓓多康生物医药科技(上海)有限公司 | Formula and preparation method of food for recuperating crowd suffering from metabolism syndromes |
| CN105106244A (en) * | 2015-08-06 | 2015-12-02 | 温州医科大学附属第二医院 | Probiotics preparation for preventing and treating diabetic encephalopathy and method for preparing probiotics preparation |
| CN106074975A (en) * | 2016-07-21 | 2016-11-09 | 无限极（中国）有限公司 | A kind of compositions and the application in preparation improves the product of function of intestinal canal thereof |
| CN106420839A (en) * | 2016-10-25 | 2017-02-22 | 山东博德生物科技有限公司 | Clostridium butyricum-inulin composition as well as preparation method and application thereof |
| CN106562998A (en) * | 2015-10-12 | 2017-04-19 | 深圳华大基因研究院 | Applications of lactobacillus crispatus in treatment or prevention of uterus myoma related diseases |
| CN106619743A (en) * | 2016-12-28 | 2017-05-10 | 山东龙力生物科技股份有限公司 | Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink |
| CN106666738A (en) * | 2016-12-13 | 2017-05-17 | 合肥赛为智慧医疗有限公司 | Composition used for improving metabolic disorder status of human body and preparation method thereof |
| CN106974939A (en) * | 2016-01-15 | 2017-07-25 | 深圳华大基因研究院 | Application of the heavy wall mushroom probiotics in fat and its relevant disease is treated and prevented |
| CN107050062A (en) * | 2016-11-08 | 2017-08-18 | 江西益盟科技有限公司 | Treat lactic bacteria composition of constipation and preparation method thereof |
| CN107136513A (en) * | 2017-05-09 | 2017-09-08 | 傅功成 | Adjust the health food of colony balance, preparation method and applications in human body |
| CN107411094A (en) * | 2017-05-12 | 2017-12-01 | 广州赛莱拉干细胞科技股份有限公司 | A kind of composition for improving enteric microorganism and the soft sweets for improving enteric microorganism |
| CN107468717A (en) * | 2017-09-28 | 2017-12-15 | 陈元秀 | A kind of blood sugar reducing preparation for human body and preparation method thereof |
| WO2018027898A1 (en) * | 2016-08-12 | 2018-02-15 | 深圳华大基因研究院 | Faecalibacterium butyricigenerans and method for cultivation thereof and application thereof |
| CN107693662A (en) * | 2017-10-18 | 2018-02-16 | 南昌大学 | A kind of probiotics aloe liquid and its for preparing burn wound medicinal usage |
| CN108125096A (en) * | 2018-01-30 | 2018-06-08 | 青岛明药堂医疗股份有限公司 | A kind of ferment solid beverage containing chitin derivativ and preparation method thereof |
| CN108295098A (en) * | 2018-02-02 | 2018-07-20 | 云南中京国建投资有限公司 | The symphysis unit composition and its preparation of a kind of auxiliary hyperglycemic and application |
| CN109846984A (en) * | 2019-04-15 | 2019-06-07 | 福州东宇生物科技有限公司 | A kind of probiotics that the multicomponent with treatment chronic gastritis function is compound |
| WO2019227418A1 (en) * | 2018-05-31 | 2019-12-05 | 深圳华大生命科学研究院 | Composition and uses thereof |
| WO2019227417A1 (en) * | 2018-05-31 | 2019-12-05 | 深圳华大生命科学研究院 | Composition and uses thereof |
| CN110638841A (en) * | 2019-09-25 | 2020-01-03 | 山东艾克韦生物技术有限公司 | Probiotics and prebiotics compound preparation, preparation method and application thereof |
| CN111450122A (en) * | 2019-11-02 | 2020-07-28 | 吉安诺惠诚莘科技有限公司 | Complex microbial inoculant and application thereof in skin repair |
| CN112274612A (en) * | 2019-09-17 | 2021-01-29 | 纽新宝药业有限公司 | Composition, use and medicament thereof |
| CN113925923A (en) * | 2021-11-25 | 2022-01-14 | 广东益可维生物技术有限公司 | Anti-acne and whitening compound probiotic composition and preparation method thereof |
| CN114246341A (en) * | 2021-12-23 | 2022-03-29 | 瘦哪儿(广东)生物科技有限公司 | Probiotic composition for improving body fat rate and preparation method thereof |
| CN114304641A (en) * | 2021-12-30 | 2022-04-12 | 武汉英纽林生物科技有限公司 | A nutritional intervention composition and its application in diabetic patients |
| CN115038341A (en) * | 2020-10-29 | 2022-09-09 | hy有限公司 | Coated probiotics, food compositions comprising the coated probiotics and methods for producing the coated probiotics |
| CN115918911A (en) * | 2023-02-09 | 2023-04-07 | 同芙集团(中国)股份有限公司 | Probiotic composition and application thereof, probiotic product and preparation method thereof |
| NL2032234B1 (en) * | 2022-06-21 | 2023-08-15 | Anhui Zhongwei Weiyuan Biological Tech Co Ltd | Active probiotics compositions preparation method |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1440239A (en) * | 2000-06-30 | 2003-09-03 | 雀巢制品公司 | Candy products containing active ingredients |
| EP2347661A1 (en) * | 2008-11-21 | 2011-07-27 | José Antonio Cruz Serrano | Method for obtaining a mixture of probiotics, nutrient prebiotics having synergistic symbiotic action |
| CN102883626A (en) * | 2009-11-25 | 2013-01-16 | 雀巢产品技术援助有限公司 | Nutritional compositions including a high protein component and exogenous nucleotides |
| CN103431376A (en) * | 2013-07-18 | 2013-12-11 | 浙江劲膳美生物科技有限公司 | Special diet edible for constipation patients |
-
2013
- 2013-12-31 CN CN201310754269.4A patent/CN104740138A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1440239A (en) * | 2000-06-30 | 2003-09-03 | 雀巢制品公司 | Candy products containing active ingredients |
| EP2347661A1 (en) * | 2008-11-21 | 2011-07-27 | José Antonio Cruz Serrano | Method for obtaining a mixture of probiotics, nutrient prebiotics having synergistic symbiotic action |
| CN102883626A (en) * | 2009-11-25 | 2013-01-16 | 雀巢产品技术援助有限公司 | Nutritional compositions including a high protein component and exogenous nucleotides |
| CN103431376A (en) * | 2013-07-18 | 2013-12-11 | 浙江劲膳美生物科技有限公司 | Special diet edible for constipation patients |
Non-Patent Citations (1)
| Title |
|---|
| "小胖子": "康宝莱芦荟营养粉益生元肠道卫士", 《BLOG.SINA.COM.CN/S/BLOG_790133F90100XKMO.HTML》 * |
Cited By (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104970317A (en) * | 2015-07-08 | 2015-10-14 | 蓓多康生物医药科技(上海)有限公司 | Formula and preparation method of food for recuperating crowd suffering from metabolism syndromes |
| CN105106244A (en) * | 2015-08-06 | 2015-12-02 | 温州医科大学附属第二医院 | Probiotics preparation for preventing and treating diabetic encephalopathy and method for preparing probiotics preparation |
| CN105106244B (en) * | 2015-08-06 | 2018-12-25 | 温州医科大学附属第二医院 | A kind of probiotics preparation and preparation method thereof for preventing and treating diabetes mellitus encephalopathy |
| CN106562998A (en) * | 2015-10-12 | 2017-04-19 | 深圳华大基因研究院 | Applications of lactobacillus crispatus in treatment or prevention of uterus myoma related diseases |
| CN106974939A (en) * | 2016-01-15 | 2017-07-25 | 深圳华大基因研究院 | Application of the heavy wall mushroom probiotics in fat and its relevant disease is treated and prevented |
| CN106074975A (en) * | 2016-07-21 | 2016-11-09 | 无限极（中国）有限公司 | A kind of compositions and the application in preparation improves the product of function of intestinal canal thereof |
| WO2018027898A1 (en) * | 2016-08-12 | 2018-02-15 | 深圳华大基因研究院 | Faecalibacterium butyricigenerans and method for cultivation thereof and application thereof |
| CN109874329B (en) * | 2016-08-12 | 2023-08-29 | 深圳华大生命科学研究院 | Fusarium butyricum and culture method and application thereof |
| CN109874329A (en) * | 2016-08-12 | 2019-06-11 | 深圳华大生命科学研究院 | A kind of production butyric acid is dwelt bacillus faecalis and its cultural method and application |
| US11191790B2 (en) | 2016-08-12 | 2021-12-07 | Bgi Shenzhen | Biologically pure Faecalibacterium butyricigenerans strain, composition including the same and method for treating ulcerative colitis |
| CN106420839A (en) * | 2016-10-25 | 2017-02-22 | 山东博德生物科技有限公司 | Clostridium butyricum-inulin composition as well as preparation method and application thereof |
| CN107050062A (en) * | 2016-11-08 | 2017-08-18 | 江西益盟科技有限公司 | Treat lactic bacteria composition of constipation and preparation method thereof |
| CN106666738A (en) * | 2016-12-13 | 2017-05-17 | 合肥赛为智慧医疗有限公司 | Composition used for improving metabolic disorder status of human body and preparation method thereof |
| CN106619743A (en) * | 2016-12-28 | 2017-05-10 | 山东龙力生物科技股份有限公司 | Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink |
| CN107136513A (en) * | 2017-05-09 | 2017-09-08 | 傅功成 | Adjust the health food of colony balance, preparation method and applications in human body |
| CN107411094A (en) * | 2017-05-12 | 2017-12-01 | 广州赛莱拉干细胞科技股份有限公司 | A kind of composition for improving enteric microorganism and the soft sweets for improving enteric microorganism |
| CN107468717A (en) * | 2017-09-28 | 2017-12-15 | 陈元秀 | A kind of blood sugar reducing preparation for human body and preparation method thereof |
| CN107693662A (en) * | 2017-10-18 | 2018-02-16 | 南昌大学 | A kind of probiotics aloe liquid and its for preparing burn wound medicinal usage |
| CN108125096A (en) * | 2018-01-30 | 2018-06-08 | 青岛明药堂医疗股份有限公司 | A kind of ferment solid beverage containing chitin derivativ and preparation method thereof |
| CN108295098A (en) * | 2018-02-02 | 2018-07-20 | 云南中京国建投资有限公司 | The symphysis unit composition and its preparation of a kind of auxiliary hyperglycemic and application |
| WO2019227417A1 (en) * | 2018-05-31 | 2019-12-05 | 深圳华大生命科学研究院 | Composition and uses thereof |
| US11376289B2 (en) | 2018-05-31 | 2022-07-05 | Bgi Shenzhen | Composition and uses thereof |
| CN112218646B (en) * | 2018-05-31 | 2024-06-11 | 深圳华大生命科学研究院 | Composition and application thereof |
| CN112218646A (en) * | 2018-05-31 | 2021-01-12 | 深圳华大生命科学研究院 | Composition and application thereof |
| CN112236155A (en) * | 2018-05-31 | 2021-01-15 | 深圳华大生命科学研究院 | Composition and application thereof |
| WO2019227418A1 (en) * | 2018-05-31 | 2019-12-05 | 深圳华大生命科学研究院 | Composition and uses thereof |
| CN109846984A (en) * | 2019-04-15 | 2019-06-07 | 福州东宇生物科技有限公司 | A kind of probiotics that the multicomponent with treatment chronic gastritis function is compound |
| CN112274612A (en) * | 2019-09-17 | 2021-01-29 | 纽新宝药业有限公司 | Composition, use and medicament thereof |
| CN110638841B (en) * | 2019-09-25 | 2024-02-20 | 山东艾克韦生物技术有限公司 | Probiotics and prebiotics composite preparation, preparation method and application thereof |
| CN110638841A (en) * | 2019-09-25 | 2020-01-03 | 山东艾克韦生物技术有限公司 | Probiotics and prebiotics compound preparation, preparation method and application thereof |
| CN111450122B (en) * | 2019-11-02 | 2023-04-25 | 吉安诺惠诚莘科技有限公司 | Composite microbial inoculum and application thereof in skin repair |
| CN111450122A (en) * | 2019-11-02 | 2020-07-28 | 吉安诺惠诚莘科技有限公司 | Complex microbial inoculant and application thereof in skin repair |
| CN115038341A (en) * | 2020-10-29 | 2022-09-09 | hy有限公司 | Coated probiotics, food compositions comprising the coated probiotics and methods for producing the coated probiotics |
| CN115038341B (en) * | 2020-10-29 | 2024-06-11 | hy有限公司 | Coated probiotics, food compositions comprising the same and methods for producing the same |
| CN113925923A (en) * | 2021-11-25 | 2022-01-14 | 广东益可维生物技术有限公司 | Anti-acne and whitening compound probiotic composition and preparation method thereof |
| CN114246341A (en) * | 2021-12-23 | 2022-03-29 | 瘦哪儿(广东)生物科技有限公司 | Probiotic composition for improving body fat rate and preparation method thereof |
| CN114304641A (en) * | 2021-12-30 | 2022-04-12 | 武汉英纽林生物科技有限公司 | A nutritional intervention composition and its application in diabetic patients |
| CN114304641B (en) * | 2021-12-30 | 2023-10-27 | 武汉英纽林生物科技有限公司 | Nutritional intervention composition and application thereof in diabetics |
| NL2032234B1 (en) * | 2022-06-21 | 2023-08-15 | Anhui Zhongwei Weiyuan Biological Tech Co Ltd | Active probiotics compositions preparation method |
| CN115918911A (en) * | 2023-02-09 | 2023-04-07 | 同芙集团(中国)股份有限公司 | Probiotic composition and application thereof, probiotic product and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104740138A (en) | Composition containing aloe, probiotics and prebiotics and application of composition | |
| Aggarwal et al. | Probiotics and their effects on metabolic diseases: an update | |
| CN104413334A (en) | Edible composition as well as preparation method and application thereof | |
| BRPI0611492A2 (en) | feline probiotic bifidobacterium | |
| BRPI0611493B1 (en) | Feline probiotic lactobacilli | |
| CN103764154A (en) | Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes | |
| CN104415060A (en) | Edible composition as well as preparation method and application thereof | |
| CN109481510A (en) | It is a kind of to help to improve diabetes B and its synbiotic compound preparation of complication and preparation method thereof | |
| CN113151056A (en) | Probiotic composition, preparation method and application thereof | |
| CN104432001B (en) | Edible composition and application thereof | |
| CN110325198A (en) | Use of probiotics in the treatment and/or prevention of psoriasis | |
| CN104415061B (en) | Edible composition and its production and use | |
| CN107951876A (en) | Purposes of the allicin in microbial population of animal intestinal tract is adjusted | |
| JP5592640B2 (en) | Antistress agent containing lactic acid bacteria fermented royal jelly, method for producing the same, hypothalamus-pituitary-adrenocortical activity inhibitor, and sympathetic-adrenal medullary activity inhibitor | |
| CN109315769A (en) | It is a kind of for improving the composition and preparation method thereof of human body enteral environment | |
| Wu et al. | Effect of a Chinese medical nutrition therapy diet on gut microbiota and short chain fatty acids in the simulator of the human intestinal microbial ecosystem (SHIME) | |
| JP4540376B2 (en) | Lactic acid bacteria production substances | |
| JP6793380B2 (en) | Evaluation method, screening method and manufacturing method of substances that suppress the rise in blood glucose level due to sucrose intake | |
| CN107095308A (en) | A kind of probiotics preparation and its application | |
| CN107118981A (en) | A kind of probiotics preparation and its application for being used to nurse one's health enteric microorganism environment | |
| CN108403970B (en) | Prebiotic composition and preparation method and application thereof | |
| CN108523123A (en) | A kind of full nutritional support food of diabetes | |
| CN104415214B (en) | Purposes of the black garlic extract in microbial population of animal intestinal tract is adjusted | |
| CN107106479A (en) | Improve the composition of the cellulite outward appearance of skin | |
| JP2024529268A (en) | Compositions containing three strains of Lactobacillus genus and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 518083 11F-3, Beishan industrial complex, 146 Beishan Road, Yantian District, Shenzhen, Guangdong Applicant after: BGI SHENZHEN Co.,Ltd. Applicant after: Shenzhen Huada Sansheng Garden Technology Co.,Ltd. Address before: 518083 11F-3, Beishan industrial complex, 146 Beishan Road, Yantian District, Shenzhen, Guangdong Applicant before: BGI SHENZHEN Co.,Ltd. Applicant before: SHENZHEN BGI AGRICULTURE AND CYCLE ECONOMIC TECHNOLOGY Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20180921 Address after: 518083 2 building, Beishan Industrial Zone, 146 Beishan Road, Yantian District, Shenzhen, Guangdong, China, 11 Applicant after: BGI SHENZHEN Co.,Ltd. Applicant after: BGI PRECISION NUTRITION (SHENZHEN) TECHNOLOGY CO.,LTD. Address before: 518083 11F-3, Beishan industrial complex, 146 Beishan Road, Yantian District, Shenzhen, Guangdong Applicant before: BGI SHENZHEN Co.,Ltd. Applicant before: Shenzhen Huada Sansheng Garden Technology Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20191213 Address after: 518120 A205, Peng Fei Road, Dapeng street, Dapeng New District, Shenzhen, Guangdong, China, 7 Applicant after: Shenzhen Huada Gene Agriculture Holding Co.,Ltd. Applicant after: BGI PRECISION NUTRITION (SHENZHEN) TECHNOLOGY CO.,LTD. Address before: 518083 2 building, Beishan Industrial Zone, 146 Beishan Road, Yantian District, Shenzhen, Guangdong, China, 11 Applicant before: BGI SHENZHEN Co.,Ltd. Applicant before: BGI PRECISION NUTRITION (SHENZHEN) TECHNOLOGY CO.,LTD. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150701 |